Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.
🔥Premium Digital Products at Prices You’ll Love 🔥
🚀Build Faster. Create Smarter. Spend Less. 🚀
💡Plug-ins, Themes & Tools Actually Perform 💡
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.
Add comment